Live feed07:33:29·384dANALYSTRatingvia QuantisnowH.C. Wainwright resumed coverage on Akebia Therapeutics with a new price targetByQuantisnow·Wall Street's wire, on your screen.AKBA· Akebia Therapeutics Inc.Health CareOriginal source